| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000 | Human,Mouse,Rat |
| Aliases | ANKRD30A; Ankyrin repeat domain-containing protein 30A; Serologically defined breast cancer antigen NY-BR-1 |
| Entrez GeneID | 91074; |
| WB Predicted band size | 153kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the C-terminal region of human ANKRD30A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于ANKRD30A抗体的3篇参考文献示例(内容基于模拟文献，建议通过学术数据库核实具体信息)：
---
1. **文献名称**：*ANKRD30A as a novel biomarker for estrogen receptor-positive breast cancer*
**作者**：Smith J, et al.
**摘要**：该研究通过免疫组化(IHC)和Western blot分析，证实ANKRD30A在雌激素受体阳性(ER+)乳腺癌组织中高表达，其抗体特异性可用于区分乳腺癌亚型及预后评估。
---
2. **文献名称**：*Role of ANKRD30A in spermatogenesis: Insights from antibody-mediated localization studies*
**作者**：Johnson R, et al.
**摘要**：利用ANKRD30A特异性抗体，研究发现该蛋白在男性生殖细胞发育中动态表达，提示其在精子形成和减数分裂调控中的潜在作用。
---
3. **文献名称**：*ANKRD30A antibody validation for cancer immunotherapy target screening*
**作者**：Lee H, et al.
**摘要**：研究验证了多种ANKRD30A抗体的特异性，并评估其在肿瘤微环境中的表达模式，为针对ANKRD30A的免疫治疗策略提供实验依据。
---
**提示**：建议通过PubMed或Google Scholar以“ANKRD30A antibody”为关键词检索最新文献，或查阅抗体供应商(如Abcam、CST)提供的引用文献列表获取具体研究。
**Background of ANKRD30A Antibody**
The ANKRD30A (Ankyrin Repeat Domain 30A) gene encodes a protein containing multiple ankyrin repeats, structural motifs involved in protein-protein interactions. Primarily expressed in estrogen receptor (ER)-positive breast cancer, testis, and thyroid tissues, ANKRD30A is classified as a cancer-testis antigen (CTA) due to its restricted expression in normal tissues and frequent reactivation in malignancies. It has been implicated in regulating cell proliferation, apoptosis, and transcriptional activity, though its precise molecular functions remain under investigation.
ANKRD30A gained attention as a potential biomarker, particularly in breast cancer, where it is associated with ER-positive tumor subtypes. Antibodies targeting ANKRD30A are widely used in research to detect its expression via techniques like immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF). These tools help elucidate its role in cancer biology and its correlation with clinical outcomes. Studies suggest ANKRD30A may influence hormone receptor signaling pathways, contributing to tumor progression or therapy resistance.
Additionally, ANKRD30A antibodies hold diagnostic and prognostic potential, as elevated expression in certain cancers may guide therapeutic strategies. Ongoing research aims to clarify its utility as a therapeutic target or companion diagnostic marker, particularly in hormone-driven malignancies. The development and validation of specific ANKRD30A antibodies continue to support advances in understanding its biological and clinical significance.
×
